## PATENT COOPERATION TREATY

# Translation

# **PCT**

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PCG-9001WO	FOR FURTHER ACTION	See Form PCT/IPEA/416
	International filing date (day/month/year)	r) Priority date (day/month/year)
PCT/JP2004/011650	06.08.2004	08.08.2003
International Patent Classification (IPC) or natio	onal classification and IPC	
	C12Q1/68, C07K14/	82, A61K31/711,
C07K16/32	, C12N5/10, G01N33	/15, G01N33/50
Applicant ABURATANI, Hiroyuki		
This report is the international prelin under Article 35 and transmitted to the	ninary examination report, established be applicant according to Article 36.	by this International Preliminary Examining Authority
2. This REPORT consists of a total of _	_	ncluding this cover sheet.
3. This report is also accompanied by Al		
	to the International Bureau) a total of _	sheets, as follows:
sheets of the descrip sheets containing red Instructions).	otion, claims and/or drawings which have ctifications authorized by this Authority	e been amended and are the basis for this report and/or (see Rule 70.16 and Section 607 of the Administrative
sheets which supers the disclosure in the Box.	ede earlier sheets, but which this Autho e international application as filed, as in	ority considers contain an amendment that goes beyond indicated in item 4 of Box No. I and the Supplemental
b. (sent to the International	Bureau only) a total of (indicate type and	d number of electronic carrier(s))
		, containing a sequence listing and/or tables
related thereto, in computer		e Supplemental Box Relating to Sequence Listing (see
This report contains indications relations.		
Box No. I Basis of the		
Box No. II Priority	•	
	ishment of opinion with regard to novelt	ty, inventive step and industrial applicability
l <u> </u>	ity of invention	
Box No. V Reasoned s	-	d to novelty, inventive step or industrial applicability;
Box No. VI Certain do	cuments cited	
Box No. VII Certain del	fects in the international application	
Box No. VIII Certain ob	servations on the international application	on
Date of submission of the demand	Date of comple	ction of this report
Name and mailing address of the IPEA/JP	Authorized offi	icer
1	Į	

International application No.

PCT/JP2004/011650

Box	No. I	Basis of the report		
1.		d to the language, this report is based on the international a under this item.	application in the language in which it was filed, unless otherwise	
		report is based on translations from the original language in		٠,
	which	h is the language of a translation furnished for the purposes	s of:	
	님	international search (Rule 12.3 and 23.1(b))		
	님	publication of the international application (Rule 12.4)		
	Ш	international preliminary examination (Rule 55.2 and/or 5		the
2.	With regard receiving ( this report)	Office in response to an invitation under Article 14 are re	ort is based on (replacement sheets which have been furnished to the ferred to in this report as "originally filed" and are not annexed to the ferred to in this report as "originally filed" and are not annexed to the ferred to	ine i to
	the it	nternational application as originally filed/furnished		
	the d	description:		
	page	es	as originally filed/furnishe	ed
	page	es* re	eceived by this Authority on	_
	page		eceived by this Authority on	_
ļ				
	<del></del>	claims:	as originally filed/furnish	ed
Ì	nos.			
	nos.	———	as amended (together with any statement) under Article	
	nos.	* r	eceived by this Authority on	_
	nos.	.* n	received by this Authority on	_
	the	drawings:		
	shee	ets	as originally filed/furnish	ned
	shee	ets* r	received by this Authority on	
	shee	ets* r	received by this Authority on	_
	⊠ a se	equence listing and/or any related table(s) – see Supplement		
		e amendments have resulted in the cancellation of:		
3.	L Ind	1		
		the description, pages		_
İ		the claims, nos.		_
		the drawings, sheets/figs		_
	<u> </u>	the sequence listing (specify):		_
		any table(s) related to sequence listing (specify):		
4.	The the	nis report has been established as if (some of) the amendmey have been considered to go beyond the disclosure as filed	nents annexed to this report and listed below had not been made, d, as indicated in the Supplemental Box (Rule 70.2(c)).	since
	<u></u>	the description, pages		_
		the claims, nos.		
		the drawings, sheets/figs		_
		the sequence listing (specify):		
		any table(s) related to sequence listing (specify):		
.	If item 4	applies, some or all of those sheets may be marked "super	rseded."	

International application No.

PCT/JP2004/011650

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:
the entire international application
claims Nos. 28-37
because:
the said international application, or the said claims Nos. 28-37 relate to the following subject matter which does not require an international preliminary examination (specify):
The subject matter of claims 28-37 relates to
methods for treatment of the human body therapy, as
well as diagnostic methods. Thus, this International
Preliminary Examining Authority is not required to
carry out international preliminary examination on
this subject matter under the provisions of PCT
Article $17(2)(a)(i)$ and PCT Rule $67.1(iv)$ .
the description, claims or drawings (indicate particular elements below) or said claims Nos.  are so unclear that no meaningful opinion could be formed (specify):
the claims, or said claims Nos are so inadequately supported
by the description that no meaningful opinion could be formed.
no international search report has been established for said claims Nos.
the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrativ Instructions in that:
the written form has not been furnished does not comply with the standard
the computer readable form has not been furnished
does not comply with the standard
the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.
See Supplemental Box for further details.

PCT/JP2004/011650

	r Article 35(2) with regard to novelty, inventive step or industrial applicability; supporting such statement	Reasoned statement under Ar citations and explanations sup	ox No. V	Box
		nent	Statement	1.
YES	ns _3	ovelty (N) Claims	Novelty (	
NO	ns 1, 2, 10, 11, 13-16, 24-27	Claims		
YES	ms	ventive step (IS) Claims	Inventive	
NO	ms 1-3, 10, 11, 13-16, 24-27	Claims		
YES	ms 1-3, 10, 11, 13-16, 24-27	dustrial applicability (IA) Claims	Industria	
NO	ms	Claims		
	1, 2, 10, 11, 13-16, 24-27  ms  1-3, 10, 11, 13-16, 24-27  ms  1-3, 10, 11, 13-16, 24-27	Claims  Claims  Claims  Claims  Claims  Claims  Claims  Claims	Inventive	

2. Citations and explanations (Rule 70.7)

Document 1: WO 02/046415 A2 (Incyte Genomics, Inc.)

Document 2: US 2003/0003538 A1 (Dietrich P.S. et al.)

Document 3: WO 03/029424 A2 (Curagen Corporation)

Parts of Claims 1, 2, 10, 11, 13 to 16 and 24 to 27 Concerning SEQ ID NO: 1

Documents 1 to 3 set forth protein coded by SEQ ID NO: 1 of this application, and fragments thereof (SEQ ID NO: 30, document 1; SEQ ID NO: 16, document 2; SEQ ID NO: 162, document 3). Documents 1 to 3 also set forth an antibody which recognizes these fragments. Documents 2 and 3 also set forth polynucleotides which code said fragments (document 2, SEQ ID NO: 15, document 3, SEQ ID NO: 161), and indicate that these polynucleotides are incorporated into vectors and transformed. Documents 2 and 3 also set forth methods of identifying anti-cancer activity.

There is therefore no discernible difference between the inventions set forth in documents 1 to 3 and the invention set forth in claims 1, 2, 10, 11, 13 to 16 and 24 to 27 of this application.

International application No.
PCT/JP2004/011650

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Part of Claim 3 Concerning SEQ ID NO: 1

Document 1 sets forth protein coded by SEQ ID NO: 1 of this application, and fragments thereof (SEQ ID NO: 30), and indicates that said protein is concerned with lung cancer (page 66, lines 27 to 29). It would therefore be easy for a person skilled in the art to conceive of employing the protein set forth in document 1 in the diagnosis and/or treatment of lung cancer.

International application No.
PCT/JP2004/011650

JOX IN	No. VI Certain documents cited				
l. <b>(</b>	Certain published documents (Rule 70.10)		· · · <del></del>		
	Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim (day/month/year)	
	WO 2004/040000 A2	13.05.2004	09.09.2003	09.09.2002	
	[E, X]				
. :	Non-written disclosures (Rule 70.9)				
			Dat	e of written disclosure	
	Kind of non-written disclosure	Date of non-written of (day/month/yet	lisclosure referring ar)	referring to non-written disclosure (day/month/year)	

International application No.

PCT/JP2004/011650

Supplemental Box Relating to Sequence Listing		
Continuation of Box No. I, item 2:		
<ol> <li>With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report was established on the basis of:</li> </ol>		
a. type of material  a sequence listing  table(s) related to the sequence listing  b. format of material  in written format  in computer readable form  c. time of filing/furnishing  contained in the international application as filed  filed together with the international application in computer readable form		
furnished subsequently to this Authority for the purposes of search and/or examination		
2. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.		
3. Additional comments:		
* If item 4 in Box No. I applies, the listing and/or table(s) related thereto, which form part of the basis of the report, may be marked "superseded."		

International application No.
PCT/JP2004/011650

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of:

(Continued from Box III)

The international search report has not been prepared for the parts of claims 4 to 9, 12, 17 to 23, 28 to 37 and claims 1 to 3, 10, 11, 13 to 16 and 24 to 27 excluding those parts relating to SEQ ID NO: 1.